164 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
NVO Novo Nordisk A/S $47.64 $114.84B N/A
Article Searches
Novo Nordisk A/S (NVO) Lars Rebien Sørensen on Q2 2016 Results - Earnings Call Transcript http://seekingalpha.com/article/3996583-novo-nordisk-s-nvo-lars-rebien-sorensen-q2-2016-results-earnings-call-transcript?source=feed_sector_healthcare Aug 05, 2016 - Novo Nordisk A/S (NYSE:NVO)Q2 2016 Earnings CallAugust 05, 2016 7:00 am ETExecutivesLars Rebien Sørensen - President & Chief Executive OfficerMads Krogsgaard Thomsen - Chief Science Officer & Executiv
Novo Nordisk's (NVO) CEO Lars Rebien Sorensen on Q1 2016 Results - Earnings Call Transcript http://seekingalpha.com/article/3969958-novo-nordisks-nvo-ceo-lars-rebien-sorensen-q1-2016-results-earnings-call-transcript?source=feed_all_articles May 01, 2016 - Novo Nordisk A/S (NYSE:NVO) Q1 2016 Earnings Conference Call April 29, 2016, 07:00 ET Executives Lars Rebien Sorensen - CEO Mads Krogsgaard Thomsen - Chief Science Officer Jesper Brandgaard - CFO Jako
Novo Nordisk A/S (NVO) Q4 2015 Results - Earnings Call Webcast http://seekingalpha.com/article/3855536-novo-nordisk-s-nvo-q4-2015-results-earnings-call-webcast?source=feed_all_articles Feb 03, 2016 -
3M Invests for Minority Stake in StrongArm Technologies http://www.zacks.com/stock/news/190601/3m-invests-for-minority-stake-in-strongarm-technologies?cid=CS-ZC-FT-190601 Sep 18, 2015 - 3M Safety and Graphics Business Group, a part of 3M Company (MMM), recently announced a minority equity investment in StrongArm Technologies Inc., - a company that designs innovative safety products.
Novo Nordisk's Victoza Fares Better than Sanofi's Lyxumia http://www.zacks.com/stock/news/190512/novo-nordisks-victoza-fares-better-than-sanofis-lyxumia?cid=CS-ZC-FT-190512 Sep 17, 2015 - Novo Nordisk (NVO) announced that a head-to-head study comparing Victoza to Sanofi's Lyxumia for the treatment of type II diabetes met its primary endpoint.
Novo Nordisk (NVO) Sees Hammer Chart Pattern: Time to Buy? http://www.zacks.com/stock/news/189330/novo-nordisk-nvo-sees-hammer-chart-pattern-time-to-buy?cid=CS-ZC-FT-189330 Sep 09, 2015 - Novo Nordisk (NVO) Sees Hammer Chart Pattern: Time to Buy?
Novartis' Farydak Gets EU Approval for Multiple Myeloma http://www.zacks.com/stock/news/189134/novartis-farydak-gets-eu-approval-for-multiple-myeloma?cid=CS-ZC-FT-189134 Sep 07, 2015 - Novartis' (NVS) Farydak (plus Velcade and dexamethasone) gets EU approval for relapsed and/or refractory multiple myeloma in treatment-experienced patients.
Bristol-Myers' (BMY) Opdivo Gets Priority Review, Shares Up http://www.zacks.com/stock/news/188930/bristol-myers-bmy-opdivo-gets-priority-review-shares-up?cid=CS-ZC-FT-188930 Sep 03, 2015 - Bristol-Myers Squibb Company (BMY) announced that the supplemental Biologics License Application for Opdivo has been accepted with priority review by the FDA.
Novartis (NVS) Launches Zarxio: First Biosimilar in the U.S. http://www.zacks.com/stock/news/188907/novartis-nvs-launches-zarxio-first-biosimilar-in-the-us?cid=CS-ZC-FT-188907 Sep 03, 2015 - Novartis (NVS) launched Zarxio (biosimilar version of Amgen's Neupogen) in the U.S., which became the first FDA-approved biosimilar to be launched in the country.
Bristol-Myers/AbbVie Cancer Drug Gets Priority Review http://www.zacks.com/stock/news/188749/bristol-myers-abbvie-cancer-drug-gets-priority-review?cid=CS-ZC-FT-188749 Sep 02, 2015 - Bristol-Myers Squibb Company (BMY) and its partner AbbVie (ABBV) announced that the BLA for Empliciti has been accepted with priority review by the FDA.

Pages: 1...11121314151617

<<<Page 16